IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (IMA901-202)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00523159
Recruitment Status : Completed
First Posted : August 31, 2007
Last Update Posted : July 10, 2012
Information provided by (Responsible Party):
immatics Biotechnologies GmbH

Brief Summary:

This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.

Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination.

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Drug: Endoxana, IMA901, Leukine Drug: IMA901 and Leukine Phase 2

Detailed Description:

This is a multicenter, open label, randomized phase 2 study which investigated the effect of a second-line systemic treatment with IMA901 plus GM-CSF in RCC patients. Randomization was done according to a pre-treatment with low-dose cyclophosphamide (CY). Secondary endpoints comprised tumor response parameters.

The study population consisted of HLA-A*02-positive men or women with advanced RCC of the clear-cell type classified as having a favorable or intermediate risk after first-line systemic therapy for. Patients had to be aged 18 years or older, had at least have one measurable tumor lesion and had have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease, during or after which the patient had experienced disease progression.

Patients in both arms received a total of 17 vaccinations with GM-CSF followed by IMA901 during the 9 month treatment period.

At screening baseline tumor status was assessed by CT or MRI. During the study tumor assessments were performed every 6 weeks.

Immunomonitoring (T-cell responses to peptides contained in IMA901 and analysis of other immune cell populations that may influence T-cell responses), serum levels of antibodies and molecules with suspected influence on immune response were assessed on several occasions during the study.

Safety assessment comprised continuous adverse event reporting, regular physical examinations and regular assessments of vital signs, hematology, blood chemistry and urine. A 12-lead ECG was performed at screening and at the end of the study. Pregnancy testing was performed according to applicable legislation in the country where the trial was performed. At the very least, women of childbearing potential had have to undergo a pregnancy test during screening for the study, before the first dose was applied and at the end of the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Study Start Date : May 2007
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Arm Intervention/treatment
Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
Drug: Endoxana, IMA901, Leukine
a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901

No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
Drug: IMA901 and Leukine
Intradermal injection of GM-CSF followed by intradermal injection of IMA901

Primary Outcome Measures :
  1. Disease control rate [ Time Frame: after 26 weeks ]

Secondary Outcome Measures :
  1. Tumor response rates and SD rate [ Time Frame: after 26 and 38 weeks ]
  2. Duration of response [ Time Frame: from the time response is first documented until the first date of recurrence or PD ]
  3. Time to response [ Time Frame: From Visit c to PR or CR ]
  4. TTP [ Time Frame: From visit C to until tumor progression ]
  5. PFS and OS [ Time Frame: From visit C to tumor progression or death ]
  6. DCR [ Time Frame: after 38 weeks on study ]
  7. Immune response [ Time Frame: Visit C, 1, 5, 6, 7, 10 and 14 ]
  8. Effect of cyclophosphamide pre-treatment on immune response [ Time Frame: Visit C, 1, 5,6,7, 10, 14 ]
  9. Safety [ Time Frame: From inclusion on the study until 3 weeks after end of study visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged at least 18 years
  • HLA type: HLA-A*02-positive
  • Histologically documented advanced clear-cell RCC
  • Patients who have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease systematic therapy for advanced disease and must be candidates for second-line therapy (NOTE: in Germany and Austria only patients after first-line tyrosine kinase inhibitor failure will be included into the study)
  • Patients having experienced documented tumor progression
  • At least one unidimensional measurable target lesion
  • Karnofsky Performance Status ≥ 80%
  • Favorable or intermediate risk according to the 3-score MSKCC criteria.
  • Able to understand the nature of the study and give written informed consent
  • Willingness and ability to comply with the study protocol for the duration of the study

Exclusion Criteria:

  • Poor risk according to the 3-score MSKCC criteria
  • Immunosuppressive therapy within 4 weeks before study entry, e.g. corticosteroid treatment
  • History of other malignant tumors, except non-melanoma-skin cancer or curatively excised cervical carcinoma in situ
  • Presence of brain metastases on MRI or CT scan
  • Patients with a history or evidence of systemic autoimmune disease
  • Any vaccination in the two weeks before study entry
  • Any planned prophylactic vaccination from study entry until the end of the induction period (5 weeks after the first vaccination)
  • Known active hepatitis B or C infection
  • Known HIV infection
  • Any other infection with a biological agent that can cause a severe disease and poses a severe danger to lab personnel working on patient tissues.
  • Any of the following in the 4 weeks before study entry:

    1. Major surgery
    2. Anticancer treatments including (but not limited to) cytotoxic chemotherapy, radiotherapy, immunotherapy, hormone therapy, tyrosine kinase inhibitors, monoclonal antibodies
    3. Unresolved toxicity from prior anticancer treatments including (but not limited to) cytotoxic chemotherapy, hormone therapy, tyrosine kinase inhibitors, monoclonal antibodies, radiotherapy, or immunotherapy
    4. Received study drug within any clinical study
  • Any of the following abnormal laboratory values:

    1. Hematology: Hb < 9 g/dL; WBC < 3 x 109/L; neutrophils < 1.5 x 109/L; lymphocytes < 1.0 x 109/L; platelets < 100 x 109/L
    2. Liver function: serum bilirubin > 1.5 x upper normal limit (unless a history of Gilbert's disease); ALAT or ASAT > 3 x upper normal limit (>5 x upper normal limit if liver metastases are present)
    3. Renal function: serum creatinine > 200 µmol/L
  • Patients with other significant diseases currently uncontrolled by treatment which might interfere with study completion, for example:

    1. Heart failure or non compensated active heart disease
    2. Severe coronary heart disease, cardiac arrhythmia requiring medication, or uncontrolled hypertension
    3. Symptomatic neurotoxicity (motor or sensory) ≥ grade 2 National Cancer Institute - Common Toxicity Criteria (NCI-CTC).
    4. Severe pulmonary dysfunction
  • Psychiatric disabilities, seizures or central nervous system disorders that may interfere with the ability to give informed consent or perform adequate follow-up in the investigator's opinion
  • Active infections requiring oral or intravenous antibiotics
  • Women or men who decline to practice a medically approved method of contraception
  • Pregnancy or breastfeeding
  • Any condition which in the judgment of the investigator would place the patient at undue risk or interfere with the results of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00523159

  Hide Study Locations
Medizinische Universität Salzburg - Universitätsklinik für Innere Medizin III
Salzburg, Austria, 5020
National Oncology Hospital - Urology
Sofia, Bulgaria, 1233
Regional Oncodispensary with inpatient sector-Sofia District
Sofia, Bulgaria, 1233
Charité Campus Mitte-Klinik für Urologie
Berlin, Germany, 10117
Charité Campus Benjamin Franklin - Medizinische Klinik III
Berlin, Germany, 12203
Zeisigwaldkliniken Bethanien Chemnitz GmbH
Chemnitz, Germany, 09130
Universitätsklinikum Essen
Essen, Germany, 45122
Klinik der Johann-Wolfgang-Goethe-Universität
Frankfurt / Main, Germany, 60590
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum (Onkologie / Hämatologie)
Hamburg, Germany, 20246
Universitätsklinikum Heidelberg - Klinik für Urologie
Heidelberg, Germany, 69120
Universitätsklinikum Schleswig Holstein - Campus Lübeck
Lübeck, Germany, 23538
Universitätsklinikum Mainz - 3. Medizinische Klinik
Mainz, Germany, 55131
Klinikum der Universität - München Großhadern
Munich, Germany, 81377
Urologische Klinik Dr. Castringius - München-Planegg
Planegg, Germany, 82152
Universitätsklinikum Tübingen - Klinik für Urologie
Tuebingen, Germany, 72076
Schwarzwald-Baar-Klinik - Abt. Hämatologie und Onkologie
Villingen-Schwenningen, Germany, 78050
DRC Gyógyszervizsgáló Központ Kft
Balatonfüred, Hungary, 8230
Semmelweis Egyetem - Urológiai Klinika
Budapest, Hungary, 1082
Bajcsy-Zsilinszky Kórház - Urológia Osztály
Budapest, Hungary, 1106
Fövárosi Önk.Szt.Imre Kórház - Belgyógyászat-Kliniko-FFarmakológia
Budapest, Hungary, 1115
Országos Onkológiai Intézet - Kemoterápia C osztály-Klinikofarmakológia
Budapest, Hungary, 1122
Debreceni Egyetem Orvos és Egészségtudományi Centrum
Debrecen, Hungary, 4012
Hajdú-Bihar Megyei Önk. Kenézy Gyula Kórház/Urológia Osztály
Debrecen, Hungary, 4043
BAZ megyei Kórház - Urológia Osztály
Miskolc, Hungary, 3501
Pécs Orvostudomanyi Egyetem - Urológiai Klinika
Pécs, Hungary, 7621
Klinika Chemioterapii Nowotworow - Uniwersytetu Medycznego
Lodz, Poland, 93509
Klinika Onkologii Wojskowego Institutu Medycznego
Warszawa, Poland, 00909
Clinic of Urology and Urological Oncology Medica University Hospital
Wroclaw, Poland, 50-043
Oncology Institute "Prof. Dr. Alexandru Trestioreanu"
Bucharest, Romania, 022328
Oncology Institute - "Prof. Dr. Alexandru Trestioreanu"
Bucharest, Romania, 022328
Oncology Institute "Prof. Dr. Ion Chiricuta"
Cluj-Napoca, Romania, 400015
Clinical County Hospital Oradea
Oradea, Romania, 4170167
National Cancer Institut - "Narodny onkologicky ustav"
Bratislava, Slovakia, 83310
Clinic of Radiotherapy and Oncology - East Slovak Oncology Institute
Kosice, Slovakia, 04191
Martin Faculty Hospital
Martin, Slovakia, 03659
Department of Clinical Oncology - Faculty Hospital with Policlinic of J.A. Reiman
Presov, Slovakia, 08181
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Hospital Universitario Puerta de Hierro
Madrid, Spain, 28035
Hospital 12 de Octubre
Madrid, Spain, 28041
Clinica Universitaria de Navarra - Servicio de Oncologia
Pamplona, Spain, 31008
University Hospital - Medicine Oncology
Geneva, Switzerland, 1211
United Kingdom
Beatson Oncology Centre
Glasgow, United Kingdom, G11 6NT
Christie Hospital NHS Trust, CRUK Department of Medical Onkology - Paterson Institute for Cancer Research
Manchester, United Kingdom, M20 4BX
University of Surrey - Postgraduate Medical School
Surrey, United Kingdom, GU2 7WG
Sponsors and Collaborators
immatics Biotechnologies GmbH
Study Director: Alexandra Kirner, PhD immatics Biotechnologies GmbH

Responsible Party: immatics Biotechnologies GmbH Identifier: NCT00523159     History of Changes
Other Study ID Numbers: EudraCT Nr: 2006-006370-25
First Posted: August 31, 2007    Key Record Dates
Last Update Posted: July 10, 2012
Last Verified: February 2010

Keywords provided by immatics Biotechnologies GmbH:
clear cell renal cell carcinoma

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists